Knowledge Library
Progress and Challenges in Tumor Vaccine Development
Introduction: Cancer is a major public health concern, and this disease is a leading cause of death worldwide. There are over 200 different types of cancer, and such complexity has slowed the rate of progress being made by researchers. Encouragingly, the emergence of immunotherapies, especially tumor vaccines, brings hope to cancer patients. Personalized tumor vaccines …Read More >
OncoWuXi Express: Large-scale Cell Panel Screening Platform for Integrated Pharmacogenomics and Bioinformatics Research
Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our large-scale cell panel screening platform for integrated pharmacogenomics and bioinformatics research. Cell viability assessment is a commonly used in …Read More >
OncoWuXi Express: In vitro and in vivo evaluation of an mRNA-encoded bispecific antibody (EpCAM/CD3)
Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration. However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >
Case Study: Clinically Relevant NASH Animal Model
In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs. Our findings indicate …Read More >
Case Study: DEL Data Combined with In Silico Deep-Learning Model
Read our newest case study on enhancing predictivity of drug-target interactions. In collaboration with Cyclica, WuXi AppTec scientists engaged in a study to understand the synergies between DNA encoded library (DEL) screening and Cyclica’s MatchMaker™ deep-learning model for protein-ligand interactions. Our findings indicate that combining experimental DEL data with computational analysis from MatchMaker™ can lead …Read More >
Faster with high-speed fragment screening — Accelerate your drug discovery campaign
In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited the exploration of this undevelopable area. Today, the combination of novel chemical modalities and advanced technical approaches has resulted in new clinical candidates from previously undruggable targets. To accelerate your drug discovery campaign, WuXi AppTec´s …Read More >